Free Trial
NASDAQ:CSCI

COSCIENS Biopharma (CSCI) Stock Price, News & Analysis

$3.14 -0.11 (-3.38%)
(As of 05:20 PM ET)

About COSCIENS Biopharma Stock (NASDAQ:CSCI)

Key Stats

Today's Range
$3.11
$3.40
50-Day Range
$3.00
$4.28
52-Week Range
$2.81
$11.10
Volume
4,532 shs
Average Volume
7,336 shs
Market Capitalization
$11.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Receive CSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CSCI Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Headlines

CSCI Stock Analysis - Frequently Asked Questions

COSCIENS Biopharma's stock was trading at $3.79 at the beginning of the year. Since then, CSCI stock has decreased by 17.2% and is now trading at $3.14.
View the best growth stocks for 2024 here
.

Shares of CSCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CSCI
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-16,550,000.00
Net Margins
-428.43%
Pretax Margin
-764.71%

Debt

Sales & Book Value

Annual Sales
$4.50 million
Book Value
$14.99 per share

Miscellaneous

Free Float
3,693,000
Market Cap
$11.62 million
Optionable
N/A
Beta
1.54
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:CSCI) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners